Genzyme Corporation Recalls Three Transplant Drug Lots Says US FDA

WASHINGTON, April 10 (Reuters) - Genzyme Corp has voluntarily recalled three lots of Thymoglobulin, its injectable drug for transplant patients, after one lot failed a stability test, the U.S. Food and Drug Administration said on Thursday.